Prostate Cancer, Version 4.2023

被引：279

作者：

Schaeffer, Edward M. ^{[1
]}

Srinivas, Sandy ^{[2
]}

Adra, Nabil ^{[3
]}

An, Yi ^{[4
]}

Barocas, Daniel ^{[5
]}

Bitting, Rhonda ^{[6
]}

Bryce, Alan ^{[7
]}

Chapin, Brian ^{[8
]}

Cheng, Heather H. ^{[9
]}

D'Amico, Anthony Victor ^{[10
]}

Desai, Neil ^{[11
]}

Dorff, Tanya ^{[12
]}

Eastham, James A. ^{[13
]}

Farrington, Thomas A. ^{[14
]}

Gao, Xin ^{[10
]}

Gupta, Shilpa ^{[15
,16
]}

Guzzo, Thomas ^{[17
]}

Ippolito, Joseph E. ^{[18
,19
]}

Kuettel, Michael R. ^{[20
]}

Lang, Joshua M. ^{[21
]}

Lotan, Tamara ^{[22
]}

Mckay, Rana R. ^{[23
]}

Morgan, Todd ^{[24
]}

Netto, George ^{[25
]}

Pow-Sang, Julio M. ^{[26
]}

Reiter, Robert ^{[27
]}

Roach, Mack ^{[28
]}

Robin, Tyler ^{[29
]}

Rosenfeld, Stan ^{[30
]}

Shabsigh, Ahmad ^{[31
,32
]}

Spratt, Daniel ^{[15
,16
]}

Teply, Benjamin A. ^{[33
]}

Tward, Jonathan ^{[34
]}

Valicenti, Richard ^{[35
]}

Wong, Jessica Karen ^{[36
]}

Shead, Dorothy A. ^{[37
]}

Snedeker, Jenna ^{[37
]}

Freedman-Cass, Deborah A. ^{[37
]}

机构：

[1] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA

[2] Stanford Canc Inst, Stanford, CA USA

[3] Indiana Univ, Melvin & Bren Simon Comprehens Canc Ctr, Indianapolis, IN USA

[4] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA

[5] Vanderbilt Ingram Canc Ctr, Vanderbilt, TN USA

[6] Duke Canc Inst, Durham, NC USA

[7] Mayo Clin, Comprehens Canc Ctr, Jacksonville, FL USA

[8] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[9] Fred Hutchinson Canc Ctr, Sunnyside, WA USA

[10] Dana Farber Brigham & Womens Canc Ctr, Mass Gen Canc Ctr, Boston, MA USA

[11] UT Southwestern Simmons Comprehens Canc Ctr, Dallas, TX USA

[12] City Hope Natl Canc Ctr, Monrovia, CA USA

[13] Mem Sloan Kettering Canc Ctr, Commack, NY USA

[14] Prostate Hlth Educ Network PHEN, Quincy, MA USA

[15] Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA

[16] Cleveland Clin Taussig Canc Inst, Cleveland, OH USA

[17] Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA

[18] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA

[19] Washington Univ, Sch Med, St Louis, MO USA

[20] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[21] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[22] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Mcadoo, PA USA

[23] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA USA

[24] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI USA

[25] UAB, ONeal Comprehens Canc Ctr, Birmingham, AL USA

[26] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[27] UCLA, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA

[28] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[29] Univ Colorado, Canc Ctr, Denver, CO USA

[30] Univ Calif San Francisco, Patient Serv Comm Chair, San Francisco, CA USA

[31] Ohio State Univ, James Canc Hosp, Comprehens Canc Ctr, Columbus, OH USA

[32] Solove Res Inst, Columbus, OH USA

[33] Fred & Pamela Buffett Canc Ctr, Omaha, NE USA

[34] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[35] UC Davis Comprehens Canc Ctr, Sacramento, CA USA

[36] Fox Chase Canc Ctr, Philadelphia, PA USA

[37] Natl Comprehens Canc Network, Rockledge, FL USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2023年 / 21卷 / 10期

关键词：

RANDOMIZED PHASE-III; MITOXANTRONE PLUS PREDNISONE; ANDROGEN-DEPRIVATION THERAPY; PLATINUM-BASED CHEMOTHERAPY; POST-HOC ANALYSIS; QUALITY-OF-LIFE; METASTASIS-FREE SURVIVAL; GETUG-AFU; 15; ABIRATERONE ACETATE; OPEN-LABEL;

D O I：

10.6004/jnccn.2023.0050

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions regarding the workup of patients with prostate cancer, risk stratification and management of localized disease, post-treatment monitoring, and treatment of recurrence and advanced disease. The Guidelines sections included in this article focus on the management of metastatic castration-sensitive disease, nonmetastatic castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC). Androgen deprivation therapy (ADT) with treatment inten-sification is strongly recommended for patients with metastatic castra-tion-sensitive prostate cancer. For patients with nonmetastatic CRPC, ADT is continued with or without the addition of certain secondary hormone therapies depending on prostate-specific antigen doubling time. In the mCRPC setting, ADT is continued with the sequential addition of certain secondary hormone therapies, chemotherapies, immunotherapies, radiopharmaceuticals, and/or targeted therapies. The NCCN Prostate Cancer Panel emphasizes a shared decision -making approach in all disease settings based on patient preferen-ces, prior treatment exposures, the presence or absence of visceral disease, symptoms, and potential side effects.

引用

页码：1067 / 1096

页数：30

共 165 条

[31] Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study [J].

Chi, Kim N. ;

Chowdhury, Simon ;

Bjartell, Anders ;

Byung Ha Chung ;

Gomes, Andrea J. Pereira de Santana ;

Given, Robert ;

Juarez, Alvaro ;

Merseburger, Axel S. ;

Ozguroglu, Mustafa ;

Uemura, Hirotsugu ;

Ye, Dingwei ;

Brookman-May, Sabine ;

Mundle, Suneel D. ;

McCarthy, Sharon A. ;

Larsen, Julie S. ;

Sun, Weili ;

Bevans, Katherine B. ;

Zhang, Ke ;

Bandyopadhyay, Nibedita ;

Agarwal, Neeraj .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (20) :2294-+

[32] Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer [J].

Chi, Kim N. ;

Agarwal, Neeraj ;

Bjartell, Anders ;

Chung, Byung Ha ;

Pereira de Santana Gomes, Andrea J. ;

Given, Robert ;

Juarez Soto, Alvaro ;

Merseburger, Axel S. ;

Ozguroglu, Mustafa ;

Uemura, Hirotsugu ;

Ye, Dingwei ;

Deprince, Kris ;

Naini, Vahid ;

Li, Jinhui ;

Cheng, Shinta ;

Yu, Margaret K. ;

Zhang, Ke ;

Larsen, Julie S. ;

McCarthy, Sharon ;

Chowdhury, Simon .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (01) :13-24

[33] Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial [J].

Chi, Kim N. ;

Protheroe, Andrew ;

Rodriguez-Antolin, Alfredo ;

Facchini, Gaetano ;

Suttman, Henrik ;

Matsubara, Nobuaki ;

Ye, Zhangqun ;

Keam, Bhumsuk ;

Damiao, Ronaldo ;

Li, Tracy ;

McQuarrie, Kelly ;

Jia, Bin ;

De Porre, Peter ;

Martin, Jsaon ;

Todd, Mary B. ;

Fizazi, Karim .

LANCET ONCOLOGY, 2018, 19 (02) :194-206

[34] Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial [J].

Clarke, Noel ;

Wiechno, Pawel ;

Alekseev, Boris ;

Sala, Nuria ;

Jones, Robert ;

Kocak, Ivo ;

Chiuri, Vincenzo Emanuele ;

Jassem, Jacek ;

Flechon, Aude ;

Redfern, Charles ;

Goessl, Carsten ;

Burgents, Joseph ;

Kozarski, Robert ;

Hodgson, Darren ;

Learoyd, Maria ;

Saad, Fred .

LANCET ONCOLOGY, 2018, 19 (07) :975-986

[35]

Clarke NW, 2022, NEJM EVID, V1, DOI [10.1056/evidoa2200043, 10.1056/EVIDoa2200043]

[36]

Clarke NW, 2023, J Clin Oncol, V41

[37] Risks and benefits of bisphosphonates [J].

Coleman, R. E. .

BRITISH JOURNAL OF CANCER, 2008, 98 (11) :1736-1740

[38] Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial [J].

Corn, Paul G. ;

Heath, Elisabeth, I ;

Zurita, Amado ;

Ramesh, Naveen ;

Xiao, Lianchun ;

Sei, Emi ;

Li-Ning-Tapia, Elsa ;

Tu, Shi-Ming ;

Subudhi, Sumit K. ;

Wang, Jennifer ;

Wang, Xuemei ;

Efstathiou, Eleni ;

Thompson, Timothy C. ;

Troncoso, Patricia ;

Navin, Nicholas ;

Logothetis, Christopher J. ;

Aparicio, Ana M. .

LANCET ONCOLOGY, 2019, 20 (10) :1432-1443

[39] Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer [J].

Davis, Ian D. ;

Martin, Andrew J. ;

Stockler, Martin R. ;

Begbie, Stephen ;

Chi, Kim N. ;

Chowdhury, Simon ;

Coskinas, Xanthi ;

Frydenberg, Mark ;

Hague, Wendy E. ;

Horvath, Lisa G. ;

Joshua, Anthony M. ;

Lawrence, Nicola J. ;

Marx, Gavin ;

McCaffrey, John ;

McDermott, Ray ;

McJannett, Margaret ;

North, Scott A. ;

Parnis, Francis ;

Parulekar, Wendy ;

Pook, David W. ;

Reaume, M. Neil ;

Sandhu, Shahneen K. ;

Tan, Alvin ;

Tan, T. Hsiang ;

Thomson, Alastair ;

Tu, Emily ;

Vera-Badillo, Francisco ;

Williams, Scott G. ;

Yip, Sonia ;

Zhang, Alison Y. ;

Zielinski, Robert R. ;

Sweeney, Christopher J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (02) :121-131

[40] Olaparib for Metastatic Castration-Resistant Prostate Cancer [J].

de Bono, J. ;

Mateo, J. ;

Fizazi, K. ;

Saad, F. ;

Shore, N. ;

Sandhu, S. ;

Chi, K. N. ;

Sartor, O. ;

Agarwal, N. ;

Olmos, D. ;

Thiery-Vuillemin, A. ;

Twardowski, P. ;

Mehra, N. ;

Goessl, C. ;

Kang, J. ;

Burgents, J. ;

Wu, W. ;

Kohlmann, A. ;

Adelman, C. A. ;

Hussain, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (22) :2091-2102

← 1 2 3 4 5 6 7 8 9 10 →